Corpus Intelligence IC Memo — HAMMOND SURGICAL LLC 2026-04-26 13:55 UTC
IC Memo — HAMMOND SURGICAL LLC
Investment Committee Memorandum | LA | 30 beds | Grade D | EBITDA uplift $2.6M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

HAMMOND SURGICAL LLC

CCN 190303 | nan, LA | 30 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

HAMMOND SURGICAL LLC is a 30-bed community hospital in nan, LA with $35.4M in net patient revenue and a -1.8% operating margin. The hospital serves a payer mix of 27.4% Medicare, 0.0% Medicaid, and 72.6% commercial.

Thesis: Turnaround. Our ML models identify $2.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -1.8% to 5.6% (+736bps).

Net Revenue HCRIS$35.4M
Current EBITDA COMPUTED$-622K
Operating Margin COMPUTED-1.8%
Occupancy HCRIS9.7%
Revenue / Bed COMPUTED$1.2M
Net-to-Gross HCRIS20.0%
Distress Probability MLnan%

2. Market Context & Competitive Position

212
LA Hospitals
-3.5%
State Median Margin
137
Comparable Hospitals

LA has 212 Medicare-certified hospitals with a median operating margin of -3.5%. The target's margin of -1.8% places it above the state median. Among 137 size-comparable peers (15-60 beds), the median margin is -3.1%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (15-60), prioritizing same-state peers. 137 hospitals in the comp set.

HospitalStateBedsRevenueMargin
HAMMOND SURGICAL LLC (Target)LA30$35.4M-1.8%
UNIVERSITY HOSPITAL & CLINICSLA52$158.9M-33.4%
SPECIALISTS HOSPITAL OF SHREVELA15$79.1M21.3%
NEW ORLEANS EAST HOSPITALLA60$77.6M-29.7%
OCHSNER BAYOU LLCLA25$76.5M-0.9%
OUR LADY OF THE ANGELS HOSPITALA36$76.2M-4.9%
CENTRAL LOUISIANA SURGICAL HOSLA24$69.1M7.7%
ABBEVILLE GENERAL HOSPITALLA44$68.5M3.4%
ST. CHARLES PARISH HOSPITALLA27$64.0M-5.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $2.6M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$744K+210bp18mo
Cost to Collect4.5%2.5%$708K+200bp12mo
Denial Rate Reduction12.0%6.5%$701K+198bp12mo
A/R Days Reduction5200.0%3800.0%$431K+122bp9mo
Clean Claim Rate88.0%96.0%$23K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$744K
Cost to Collect
$708K
Denial Rate Reduction
$701K
A/R Days Reduction
$431K
Clean Claim Rate
$23K
Total EBITDA Uplift$2.6M
Current EBITDA$-622K
+ RCM Uplift+$2.6M
Pro Forma EBITDA$2.0M
Current Margin-1.8%
Pro Forma Margin5.6%
WC Released (1x)$1.4M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-957K$22.0M0.00x-100.0%
Base (11x exit)10.0x11.0x$-957K$23.9M0.00x-100.0%
Bull Case9.0x11.0x$-861K$32.1M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-861K$34.8M0.00x-100.0%
Bear Case11.0x10.0x$-1.1M$9.2M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-1.1M$9.8M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumLow occupancyAt 9.7%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 137 hospitals with 15-60 beds
  • Same-state prioritization (n=138)
  • Comp margins: P25=-17.2% / P50=-3.1% / P75=6.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.